Chimerix (CMRX) Competitors $2.81 -0.10 (-3.44%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CMRX vs. AVDL, SEPN, COLL, BCAX, ZYME, GYRE, COGT, PSTX, PAHC, and NUVBShould you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Avadel Pharmaceuticals (AVDL), Septerna (SEPN), Collegium Pharmaceutical (COLL), Bicara Therapeutics (BCAX), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Cogent Biosciences (COGT), Poseida Therapeutics (PSTX), Phibro Animal Health (PAHC), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Chimerix vs. Avadel Pharmaceuticals Septerna Collegium Pharmaceutical Bicara Therapeutics Zymeworks Gyre Therapeutics Cogent Biosciences Poseida Therapeutics Phibro Animal Health Nuvation Bio Avadel Pharmaceuticals (NASDAQ:AVDL) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment. Which has better earnings and valuation, AVDL or CMRX? Chimerix has lower revenue, but higher earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$138.16M7.48-$160.28M-$0.79-13.58Chimerix$159K1,589.43-$82.10M-$0.94-2.99 Does the media favor AVDL or CMRX? In the previous week, Chimerix had 5 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 20 mentions for Chimerix and 15 mentions for Avadel Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 1.18 beat Chimerix's score of 0.22 indicating that Avadel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chimerix 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is AVDL or CMRX more profitable? Chimerix has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. Chimerix's return on equity of -50.78% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-52.53% -93.34% -44.77% Chimerix N/A -50.78%-44.94% Does the MarketBeat Community favor AVDL or CMRX? Chimerix received 51 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. However, 66.02% of users gave Avadel Pharmaceuticals an outperform vote while only 63.80% of users gave Chimerix an outperform vote. CompanyUnderperformOutperformAvadel PharmaceuticalsOutperform Votes34266.02% Underperform Votes17633.98% ChimerixOutperform Votes39363.80% Underperform Votes22336.20% Do institutionals & insiders believe in AVDL or CMRX? 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 4.8% of Avadel Pharmaceuticals shares are owned by company insiders. Comparatively, 13.1% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, AVDL or CMRX? Avadel Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Do analysts recommend AVDL or CMRX? Avadel Pharmaceuticals currently has a consensus target price of $24.43, indicating a potential upside of 127.67%. Chimerix has a consensus target price of $8.50, indicating a potential upside of 202.49%. Given Chimerix's higher probable upside, analysts clearly believe Chimerix is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Chimerix 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryChimerix beats Avadel Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRX vs. The Competition Export to ExcelMetricChimerixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$252.72M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-2.9910.80135.3117.54Price / Sales1,589.43287.861,260.42139.42Price / CashN/A56.6540.5837.95Price / Book1.295.394.884.92Net Income-$82.10M$152.04M$118.89M$225.78M7 Day Performance-5.70%-4.32%15.96%-1.56%1 Month Performance219.32%2.80%15.87%6.68%1 Year Performance195.76%17.30%34.78%22.48% Chimerix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRXChimerix4.3894 of 5 stars$2.81-3.4%$8.50+202.5%+189.7%$252.72M$159,000.00-2.9972Short Interest ↓AVDLAvadel Pharmaceuticals2.7809 of 5 stars$10.92+5.1%$24.43+123.7%-23.3%$1.05B$138.16M-13.15154Short Interest ↑Positive NewsSEPNSepterna1.7246 of 5 stars$22.24-0.7%$43.67+96.3%N/A$987.46MN/A0.00N/ACOLLCollegium Pharmaceutical3.9712 of 5 stars$30.55+1.5%$42.60+39.4%+4.3%$985.24M$599.25M12.97210News CoveragePositive NewsBCAXBicara TherapeuticsN/A$17.67+1.0%$43.00+143.4%N/A$961.53MN/A0.0032ZYMEZymeworks3.0526 of 5 stars$13.82+9.9%$18.83+36.3%+46.9%$951.92M$76.01M-9.25290Analyst UpgradePositive NewsGYREGyre Therapeutics0.3745 of 5 stars$10.15+5.3%N/A-54.6%$949.24M$105.03M0.0040News CoverageGap UpCOGTCogent Biosciences2.265 of 5 stars$8.47+3.9%$14.83+75.1%+67.8%$935.60MN/A-3.2980Short Interest ↑PSTXPoseida Therapeutics3.7029 of 5 stars$9.52+0.1%$9.50-0.2%+193.2%$930.77M$64.70M-15.10260PAHCPhibro Animal Health4.1953 of 5 stars$22.92+1.1%$19.00-17.1%+97.9%$928.33M$1.05B52.561,940Analyst ForecastNews CoverageNUVBNuvation Bio1.9641 of 5 stars$2.71+3.8%$6.60+143.5%+99.6%$912.11MN/A0.0060 Related Companies and Tools Related Companies Avadel Pharmaceuticals Competitors Septerna Competitors Collegium Pharmaceutical Competitors Bicara Therapeutics Competitors Zymeworks Competitors Gyre Therapeutics Competitors Cogent Biosciences Competitors Poseida Therapeutics Competitors Phibro Animal Health Competitors Nuvation Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
